FDA releases draft guidance on reducing testing on non-human primates for monoclonal antibodies

Professional societies, cancer advocacy groups urge NIH to withdraw proposed changes to peer-review process

The American Society of Clinical Oncology and the American Lung Association are urging caution about proposed changs to the NIH peer review process.

October 23, 2026

Vol.52 No.39

Cancer Policy

Trump signs executive order to establish the NIH Women’s Health Division and task force

President Trump earlier this week signed an executive order to create a women’s health division within NIH, as well as a White House Women’s Health Task Force.

October 23, 2026

Vol.52 No.39

By Claire Marie Porter

In Brief

Jessica Zeller named director of the Office of Compliance and Enforcement, FDA Center for Tobacco Products

Jessica Zeller was named director of the Office of Compliance and Enforcement at the FDA Center for Tobacco Products.

October 23, 2026

Vol.52 No.39

In Brief

UIC receives $5.3 million NIH grant to study population genomic cancer screenings

Knowing your genetic risk for diseases like cancer can spur detection, prevention, and treatment. But some people don’t know or have access to their family’s medical history.

October 23, 2026

Vol.52 No.39

Drugs & Targets

FDA approves pembro or pembro + berahyaluronidase alfa-pmph for unresectable or metastatic TMB-H solid tumors with updated indication

FDA has granted a traditional approval to pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for adult and pediatric patients with unresectable or metastatic tumor mutational burden-high [≥13 mutations/megabase] solid tumors, as determined by an FDA-authorized test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.

October 23, 2026

Vol.52 No.39

Drugs & Targets

FDA approves bepirovirsen, first-of-its-kind chronic hepatitis B treatment

FDA has approved Hibsago (bepirovirsen) for the treatment of chronic hepatitis B virus infection in combination with nucleos(t)ide analogue reverse transcriptase inhibitor therapy in adult patients without cirrhosis, receiving Nrtl therapy for at least 6 months, who have suppressed HBV deoxyribonucleic acid, and with hepatitis B virus surface antigen levels ≤3000 IU/ml, as determined by an FDA-authorized test.

October 23, 2026

Vol.52 No.39

FDA releases draft guidance on reducing testing on non-human primates for monoclonal antibodies

YOU MAY BE INTERESTED IN

Professional societies, cancer advocacy groups urge NIH to withdraw proposed changes to peer-review process

Trump signs executive order to establish the NIH Women’s Health Division and task force

Jessica Zeller named director of the Office of Compliance and Enforcement, FDA Center for Tobacco Products

UIC receives $5.3 million NIH grant to study population genomic cancer screenings

FDA approves pembro or pembro + berahyaluronidase alfa-pmph for unresectable or metastatic TMB-H solid tumors with updated indication

FDA approves bepirovirsen, first-of-its-kind chronic hepatitis B treatment

Renew today!

Subscriber content

Never miss an issue!

Login